

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| OMB APPROVAL | | | |
|------------------------------------|-----------|--|--|
| OMB Number: | 3235-0104 | | |
| Estimated average burden hours per | | | |
| | 0.5 | | |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of

| Name and Address of Re Sofer Gad | porting Person – | | (Month/Day/Year) 10/15/2014 | onth/Day/Year) | | Atara Biotherapeutics, Inc. [ATRA] | | | | | |
|---|--------------------|----------|---|--|--|------------------------------------|---|---|--|--|--|
| 3260 BAYSHORE BO | (First) ULEVARD | (Middle) | - 10/13/2014 - | | | (Check all applicable) | | | 5. If Amendment, Date Original Filed(Month/Day/Year) | | |
| | (Street) | | | | Director10% Owner X Officer (give title below) Other (specify below) Chief Operating Officer | | _X_Form file | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person | | | |
| BRISBANE, CA 94005 | | | | | | | | Form file | d by More than One Reporting Person | | |
| (City) | (State) | (Zip) | | Table I - Non-Derivative Securities Beneficially Owned | | | | | | | |
| 1.Title of Security (Instr. 4) | | | | 2. Amo (Instr. 4 | | | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | | Beneficial Ownership | | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | |
| 1. Title of Derivative Secur | ity | | 2. Date Exercisable | 3. Title | e and Amount | of Securities | 4. Conversion or | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership | | |
| (Instr. 4) | | | and Expiration Date (Month/Day/Year) | Underlying Derivative Security (Instr. 4) | | Derivative Security | of Derivative Security: Direct (D) | (Instr. 5) | | | |
| | | | Date Expiration Exercisable Date | Title | Amount or Nu | umber of Shares | | or Indirect (I) (Instr. 5) | | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | |
|--------------------------------|---------------|-----------|-------------------------|-------|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | |
| Sofer Gad | | | | | |
| 3260 BAYSHORE BOULEVARD | | | Chief Operating Officer | | |
| BRISBANE, CA 94005 | | | | | |

Signatures

| /s/ Tina Gullotta, Attorney-in-Fact for Gad Soffer | 10/15/2014 |
|--|------------|
| **Signature of Reporting Person | Date |

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

As described in the issuer's registration statement on Form S-1 (File No. 333-

196936) for the issuer's initial public offering (the "IPO"), the Reporting Person holds 220,178 restricted stock units (the "RSUs"), the vesting of which are subject to the satisfaction of both (a) a serv based condition and (b) a liquidity event-based condition. As a result, RSUs are not yet considered reportable for purposes of Section 16, and are not reflected on this Form 3. The liquidity event-based condition of the RSUs will be satisfied upon the closing of the IPO.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Atara Biotherapeutics, Inc. (the "Company"), hereby constitutes and appoints John McGrath, Tina Gullotta and Kim Merritt the undersigned's true and lawful attorneys-in-fact to:

- 1. Complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- 2. Do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

The undersigned hereby terminates all prior powers of attorney regarding the subject matter hereof.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of July 18, 2014.

Signature: /s/ Gad Soffer

Gad Soffer